

Robert Weinstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9046251/publications.pdf>

Version: 2024-02-01

42
papers

1,715
citations

567281

15
h-index

315739

38
g-index

42
all docs

42
docs citations

42
times ranked

1256
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American Society for Apheresis. <i>Journal of Clinical Apheresis</i> , 2010, 25, 83-177.	1.3	441
2	Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American society for apheresis. <i>Journal of Clinical Apheresis</i> , 2007, 22, 106-175.	1.3	308
3	Transfusion-related acute lung injury after the infusion of IVIG. <i>Transfusion</i> , 2001, 41, 264-268.	1.6	132
4	Complications of therapeutic plasma exchange: A recent assessment. <i>Journal of Clinical Apheresis</i> , 1994, 9, 1-5.	1.3	123
5	Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. <i>Muscle and Nerve</i> , 2001, 24, 778-786.	2.2	80
6	Prevention of citrate reactions during therapeutic plasma exchange by constant infusion of calcium gluconate with the return fluid. <i>Journal of Clinical Apheresis</i> , 1996, 11, 204-210.	1.3	79
7	Therapeutic apheresis in neurological disorders. <i>Journal of Clinical Apheresis</i> , 2000, 15, 74-128.	1.3	66
8	Phytanic acid storage disease (Refsum's disease): Clinical characteristics, pathophysiology and the role of therapeutic apheresis in its management. , 1999, 14, 181-184.		53
9	Hypocalcemic toxicity and atypical reactions in therapeutic plasma exchange. <i>Journal of Clinical Apheresis</i> , 2001, 16, 210-211.	1.3	50
10	Is group A thawed plasma suitable as the first option for emergency release transfusion? (CME). <i>Transfusion</i> , 2014, 54, 1751-1755.	1.6	44
11	Treatment of high-risk, refractory acquired methemoglobinemia with automated red blood cell exchange. <i>Journal of Clinical Apheresis</i> , 1998, 13, 28-31.	1.3	43
12	Thrombotic thrombocytopenic purpura following coronary artery bypass graft surgery: Prospective observations of an emerging syndrome. <i>Journal of Clinical Apheresis</i> , 1997, 12, 159-164.	1.3	35
13	Pentastarch as partial replacement fluid for therapeutic plasma exchange: Effect on plasma proteins, adverse events during treatment, and serum ionized calcium. <i>Journal of Clinical Apheresis</i> , 1999, 14, 114-121.	1.3	34
14	Therapeutic plasma exchange performed in tandem with hemodialysis for patients with M-protein disorders. <i>Journal of Clinical Apheresis</i> , 2006, 21, 100-104.	1.3	27
15	Growth factor responses of human arterial endothelial cells in vitro. <i>In Vitro Cellular & Developmental Biology</i> , 1986, 22, 549-556.	1.0	24
16	Prospective surveillance of D recipients of D+ apheresis platelets: alloimmunization against D is not detected. <i>Transfusion</i> , 2015, 55, 1327-1330.	1.6	21
17	Successful management of paraprotein-associated peripheral polyneuropathies by immunoadsorption of plasma with staphylococcal protein A. <i>Journal of Clinical Apheresis</i> , 1993, 8, 72-77.	1.3	14
18	Therapeutic apheresis in neurological disorders: A survey of the evidence in support of current category I and II indications for therapeutic plasma exchange. <i>Journal of Clinical Apheresis</i> , 2008, 23, 196-201.	1.3	14

#	ARTICLE	IF	CITATIONS
19	Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute guillain-barré syndrome?. Journal of Clinical Apheresis, 1995, 10, 150-157.	1.3	12
20	Long-term therapeutic plasma exchange in the outpatient setting using an implantable central venous access device. Journal of Clinical Apheresis, 2004, 19, 180-184.	1.3	11
21	Prospective investigation of a subcutaneous, implantable central venous access device for therapeutic plasma exchange in adults with neurological disorders. Journal of Clinical Apheresis, 2002, 17, 1-6.	1.3	11
22	Evidence-Based Review of Therapeutic Plasma Exchange in Neurological Disorders. Seminars in Dialysis, 2012, 25, 132-139.	1.3	9
23	Regional editorial: IT programmes and policies in the Asia-Pacific region. Journal of Computer Assisted Learning, 2001, 17, 1-3.	5.1	8
24	Automated red blood cell exchange for acute drug removal in a patient with sirolimus toxicity. Journal of Clinical Apheresis, 2015, 30, 367-370.	1.3	8
25	Physiological measurements corroborate symptomatic improvement after therapeutic leukapheresis in a pregnant woman with chronic myelogenous leukemia. Journal of Clinical Apheresis, 2016, 31, 393-397.	1.3	8
26	How to write an abstract and present it at the annual meeting. , 1999, 14, 195-199.		7
27	Safety and efficacy of autologous hemopoietic progenitor cell collection in tandem with hemodialysis in multiple myeloma with myeloma cast nephropathy. Journal of Clinical Apheresis, 2014, 29, 83-89.	1.3	7
28	Prophylactic infusion of calcium gluconate to prevent a symptomatic fall in plasma ionized calcium during therapeutic plasma exchange: A comparison of two methods. Journal of Clinical Apheresis, 2018, 33, 600-603.	1.3	7
29	Response of patients with IgM and IgA-associated peripheral polyneuropathies to ?off-line? immunoadsorption treatment using the Prosorbä½ protein A column. , 1999, 14, 159-162.		6
30	A liquid calcium+vitamin D₃ supplement is effective prophylaxis against hypocalcemic toxicity during apheresis platelet donation. Journal of Clinical Apheresis, 2018, 33, 60-64.	1.3	6
31	Therapeutic plasma exchange performed in tandem with hemodialysis without supplemental calcium in the apheresis circuit. Journal of Clinical Apheresis, 2017, 32, 154-157.	1.3	4
32	How to write a manuscript for peer review. Journal of Clinical Apheresis, 2020, 35, 358-366.	1.3	4
33	Therapeutic apheresis using a mononuclear cell program to lower the microfilaria burden of a 23-year-old African woman with loiasis. Journal of Clinical Apheresis, 2017, 32, 200-202.	1.3	3
34	Dietary citrate and plasma ionized calcium: Implications for platelet donors. Journal of Clinical Apheresis, 2018, 33, 222-225.	1.3	3
35	Performance characteristics of the PowerFlow apheresis port: Early experience. Journal of Clinical Apheresis, 2019, 34, 661-665.	1.3	3
36	Therapeutic leukocytapheresis for improvement in respiratory function in a woman with hyperleukocytosis and mantle cell lymphoma with a circulating small lymphocyte phenotype. Journal of Clinical Apheresis, 2016, 31, 398-402.	1.3	2

#	ARTICLE	IF	CITATIONS
37	Automated red blood cell exchange in preparation for filgrastim mobilization of autologous peripheral blood hematopoietic progenitor cells in a patient with sickle cell anemia. Journal of Clinical Apheresis, 2018, 33, 431-435.	1.3	2
38	Optimization of infusional calcium gluconate for prevention of hypocalcemic reactions during therapeutic plasma exchange. Journal of Clinical Apheresis, 2019, 34, 656-660.	1.3	2
39	Writing scientific case reports for top-line journals. Journal of Clinical Apheresis, 2021, 36, 465-469.	1.3	2
40	Surviving peer review. Journal of Clinical Apheresis, 2020, 35, 469-476.	1.3	1
41	Thrombotic thrombocytopenic purpura following coronary artery bypass graft surgery: Prospective observations of an emerging syndrome. Journal of Clinical Apheresis, 1997, 12, 159-164.	1.3	1
42	Therapeutic phlebotomy and specialized hemapheresis. , 2016, , 407-417.		0